Our Research

Bio Technology

Please use selectors to filter reports

December 16, 2021
Equity Research Coverage

Chimeric Therapeutics Limited (ASX: CHM) – Initiating Coverage

Chimeric Therapeutics Limited (ASX: CHM) is a clinical stage cell therapy company. CHM commenced trading on the ASX on 18 January 2021. The Company raised $35m through the issue ...................
Register to Dowload
December 14, 2021
Equity Research Coverage

Radiopharm Theranostics Limited (ASX:RAD)- Initiating Coverage

Radiopharm Theranostics Limited (ASX: RAD) is a clinical stage pharmaceutical company that focuses on the development of radiopharmaceuticals, which are radioisotopes bound to molecules to diagnose and treat diseases........
Register to Dowload
March 2, 2021
Equity Research Coverage

IIR Pharma & Biotech Index

We thought we’d kick off the year by taking a look at the top performing companies in the index for 2020. The top 10 performers are tabled below. There were some impressive returns for some of the companies in the index with 29 companies share prices rising by 100% or more....
Register to Dowload
August 24, 2020
Equity Research Coverage

Prescient Therapeutics Limited (ASX: PTX) – Next Gen CAR-T Platform a Potential Game Changer

PTX is a clinical stage oncology company with a focus on developing targeted and cellular cancer therapies. Targeted therapies are a focus for anticancer drug development, with the aim of personalising treatment based on a person’s genes and proteins to prevent, diagnose and treat the disease...
Register to Dowload
June 18, 2020
Equity Research Coverage

Pharma and Biotech Stocks on the Move – A Review of the Small Cap Stocks in the Sector on the ASX — June 2020

The coronavirus pandemic has seen unprecedented measures put in place, the ramifications of which has stretched far and wide. Pharma and biotech has been not been immune to the impacts of coronavirus. One of the key disruptions has been delays to clinical trials with access to participants restricted and hospital resources prioritised for coronavirus patients...
Register to Dowload
October 5, 2018
Equity Research Coverage

Race Oncology Limited (ASX: RAC) – Bisantrene Produced for Named Patient Program – Drug Available in Europe, UK and South Korea for the Treatment of AML

Our base case valuation for RAC has been reduced from $0.44 in our last report released in September 2017 to $0.40 per share. Our valuation is based on a fully diluted basis. The reduction in the valuation is primarily a result of the increase in the discount rate from 12.4% to 17.4%, driven primarily by an increase to the beta from 1.1 to 1.5. The company now has three key value drivers: (1) NPP Sales, (2) FDA approval of Bisantrene, and (3) RPD designation and PRV....
Register to Dowload
November 12, 2017
Company Profile Reporting

Creso Pharma Limited (ASX: CPH) – Mernova Acquisition Provides Direct Access To Canadian Market –

The company is set to launch its hemp-based animal health products in Switzerland through an exclusive commercialisation agreement with Virbac Switzerland AG (Virbac), a global pharmaceutical animal health company....
Register to Dowload
October 9, 2017
Equity Research Coverage

Sienna Cancer Diagnostics Limited (ASX: SDX) – IVD Test for Bladder Cancer – Distribution Agreements in the US & Europe

We have determined a base case valuation for SDX of $0.31 per share. The valuation incorporates a number of assumptions regarding the sales of the IVD product for the detection of bladder cancer in the US and Europe. The product has been de-risked to a large extent given the company has obtained an IVD classification in the US, Europe and Australia....
Register to Dowload
September 22, 2017
Equity Research Coverage

Race Oncology Limited (ASX: RAC) – Big Strides in the Re-Development of Bisantrene – Target Available for use in Europe & South Korea in 2 years

Our base case valuation for RAC remains at $0.44 per share. Our valuation is based on a fully diluted basis. The company is expected to generate revenue over the shortterm through the sale of Bisantrene under the NPP throughout the four above mentioned countries.RAC intends to make Bisantrene available for use in Europe and South Korea. The company is also seeking to gain approval by the FDA for its drug via the 505(b)(2) route....
Register to Dowload